TONIX PHARMACEUTICALS HOLDING CORP. 8-K

Exhibit 99.01

© 2025 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward - looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward - looking words such as “anticipate,” “believe,” “forecast,” “estimate” and “intend,” among others. These forward - looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward - looking statements. These factors include, but are not limited to , the risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; risks related to the failure to successfully launch and commercialize Tonmya and any of our approved products; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The forward - looking statements in this presentation are made as of the date of this presentation, even if subsequently made available by Tonix on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward - looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10 - K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18 , 202 5 , and periodic reports and current reports filed with the SEC on or after the date thereof. All of Tonix's forward - looking statements are expressly qualified by all such risk factors and other cautionary statements.

© 2025 Tonix Pharmaceuticals Holding Corp. 3 Our Mission Committed to improving health by discovering, developing and delivering impactful solutions, through robust in - house capabilities and synergistic collaborations, to address important unmet needs in chronic pain, nociplastic pain, immunology / immuno - oncology, infectious disease and rare disease.

© 2025 Tonix Pharmaceuticals Holding Corp. 4 Infectious disease Approved Phase 3 Phase 2 Phase 1 Preclinical Indication Product * Treatment of Fibromyalgia TONMYA TM Treatment of Acute Stress Disorder TNX - 102 SL Cyclobenzaprine HCl Sublingual Tablets Treatment of Major Depressive Disorder TNX - 102 SL Cyclobenzaprine HCl Sublingual Tablets Treatment of Acute Migraine TOSYMRA ® Treatment of Acute Migraine ZEMBRACE ® Prevention of Organ Transplant Rejection/Treatment of Autoimmune Conditions TNX - 1500 Anti - CD40L mAb Preclinical Treatment of Gastric and Colorectal Cancer TNX - 1700 TFF2 - HSA Fusion Protein Seasonal Prevention of Lyme Disease TNX - 4800 Monoclonal Antibody Preclinical Prevention of Mpox or Smallpox TNX - 801 Live Virus Horsepox Vaccine Preclinical Protection of the Warfighter From Viral Pathogens TNX - 4200 Broad Spectrum Antiviral Treatment of Prader - Willi Syndrome TNX - 2900 Intranasal Potentiated Oxytocin With Magnesium Fully Integrated Biotech: Key Commercial, Clinical, and Preclinical Programs * Tonix’s unapproved product candidates (TNX - 102 SL, TNX - 1500, TNX - 1700, TNX - 4800, TNX - 801, TNX - 4200, and TNX - 2900) are investigational n ew drugs or biologics; their safety and efficacy have not been established for the indications listed. **Investigator - initiated study. ***Pending IND filing planned for Q4 2025. Topline Reported 1st Quarter 2025 Topline Expected 2 nd Half 2026 TONMYA FDA Approved on August 15, 2025 Ph 2 Study Planned for 2026 Phase 2/3 Study Planned Phase 2 Study Enrolling** CNS US Launch Planned Q4 2025 Phase 1 Study Completed Rare disease Phase 2 Study Ready*** Immunology and Immuno - oncology

© 2025 Tonix Pharmaceuticals Holding Corp. 6 AVAILABILIT Y INDICATION MEDICINE Fibromyalgia in Adults tonmya.com CNS Medicines Acute Migraine With or Without Aura in Adults Who Have Been Diagnosed With Migraine tosymra - hcp.com Acute Migraine With or Without Aura in Adults Who Have Been Diagnosed With Migraine zembrace - hcp.com Approved Medicines FDA approved on August 15, 2025; expected availability Q4 2025 Available Available

© 2025 Tonix Pharmaceuticals Holding Corp. 8 TONMYA is the First FDA - Approved Medicine for the Treatment of Fibromyalgia in Over 15 Years First - in - class, First - line Medicine for Fibromyalgia Unique, Sublingual, Proprietary Formulation of Cyclobenzaprine HCl Designed to Optimize Efficacy, Delivery and Absorption • Two pivotal studies demonstrated durable reduction in fibromyalgia pain (primary endpoint) • Non - opioid analgesic; not DEA scheduled • Rapid drug exposure following once daily sublingual administration, at bedtime • Reduced levels of norCyclobenzaprine ( norCBP ), the active major metabolite of cyclobenzaprine ‒ norCBP is believed to reduce the effectiveness of swallowed cyclobenzaprine on pain relief • Generally well tolerated • Patent Protection / Exclusivity: Tonix owns worldwide rights to TONMYA with no royalties. In the US, issued composition of matter patent extending to 2034; pending method of use patents may extend exclusivity to 2044

© 2025 Tonix Pharmaceuticals Holding Corp. 9 Fibromyalgia is a Large, Underserved and Dissatisfied Population 2.7 million patients diagnosed and treated annually 5 ~15 million prescriptions are written for the treatment of fibromyalgia (on - and off - label usage) each year 6 Patients have expressed dissatisfaction with currently available therapies 3,4 85% of first - line treatments fail with patients, citing efficacy and tolerability issues 4 High patient churn on currently available fibromyalgia treatments Typical for patients to rotate between different therapies 79% of patients are on multiple therapies 4 1 Fibromyalgia. American College of Rheumatology. Accessed July 3, 2025. www.ACRPatientInfo.org 2 Fibromyalgia prevalence. National Fibromyalgia Association. Accessed July 3, 2025. 3 Robinson RL, et al. Pain Med . 2012 13(10):1366 - 76. doi : 10.1111; 85% received drug treatment 4 EVERSANA primary physician research, May 2024; commissioned by Tonix 5 EVERSANA analysis of claims database, May 2024, commissioned by Tonix. 6 Symphony Market data, May 2025. Prescription data includes on - label FM prescriptions and patients with FM diagnoses who receive d commonly prescribed off - label therapies >10 million U.S. adults are affected – predominantly women 1,2 Debilitating and life - altering condition Significant economic impact No new FDA approved fibromyalgia therapies in over 15 years 4 Chronic pain disorder, resulting from amplified sensory and pain signaling within the central nervous system - a serious condition comprised of the symptoms: chronic widespread pain, nonrestorative sleep, and fatigue

© 2025 Tonix Pharmaceuticals Holding Corp. 10 • Infection - Associated Chronic Conditions (IACCs) 1,2 – also known as Post - Acute Infection Syndromes (PAISs) 3 • Long COVID - ”The National Academies of Science, Engineering and Medicine (NASEM) concluded that fibromyalgia is a “diagnosable condition” in Long COVID (2024) 1 • Chronic Lyme - The NASEM report on Chronic Lyme found that fibromyalgia coexists in a subset of patients (2025) 2 • Autoimmune disease • Systemic lupus erythematosus • Rheumatoid arthritis • Cancer and cancer chemotherapy • Chronic Overlapping Pain Syndromes (COPCs) • CFS/ME (chronic fatigue syndrome/ myalgic encephalomyelitis) • Pelvic pain (cystitis) • Mild TBI / Post - concussive syndrome (PCS) 4 Conditions Commonly Comorbid with Fibromyalgia 1 NASEM. 2024. A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. Washington, DC: The Natio nal Academies Press. https://doi.org/10.17226/27768 . 2 NASEM. 2025. Charting a Path Toward New Treatments for Lyme Infection - Associated Chronic Illnesses. Washington, DC: The National Academies Press. https://doi.org/10.17226/28578 3 Choutka J, et al. Nat Med. 2022. 28(5):911 - 923. doi : 10.1038/s41591 - 022 - 01810 - 6. 4 Kureshi S, et al. Healthcare (Basel). 2024. 2(3):289. doi : 10.3390/healthcare12030289.

© 2025 Tonix Pharmaceuticals Holding Corp. 11 TONMYA Prescribing Information Highlights For full prescribing information and safety information, please visit www. t onmya.com TONMYA (cyclobenzaprine hydrochloride sublingual tablets) TONMYA is indicated for the treatment of fibromyalgia in adults Indications and Usage The recommended dosage of TONMYA is 5.6 mg administered sublingually once daily at bedtime: • Starting dose: Days 1 to 14, administer 2.8 mg (1 sublingual tablet) once daily at bedtime • Target dose: Days 15 and thereafter, administer 5.6 mg (2 sublingual tablets) once daily at bedtime The recommended TONMYA dosage in geriatric patients and patients with mild hepatic impairment is 2.8 mg administered sublingually once daily at bedtime. TONMYA is not recommended in patients with moderate or severe hepatic impairment Pregnancy testing is recommended in females of reproductive potential prior to initiating treatment with TONMYA Dosage and Administration Most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA - treated patients compared to placebo - treated patients): oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer Adverse Reactions

© 2025 Tonix Pharmaceuticals Holding Corp. 12 FDA Approval Based on Studies that Demonstrated Durable Improvement in Pain Intensity Scores in Fibromyalgia Patients CI = confidence interval; LS = least squares; SD = standard deviation; SE = standard error 1 LS means, differences and CIs were based on a mixed model for repeated measures with fixed, categorical effects of treatment, c enter, study week, and treatment - by - study week interaction, as well as the fixed covariates of baseline value and baseline value - by - study week interactions. An unstructured co variance matrix was used. 2 Difference of - 0.7 is due to a rounding effect: TONMYA: - 1.82, placebo: - 1.16, and the difference in LS mean is - 0.66. Primary Efficacy Endpoint: Mean Change from Baseline in Weekly Average of Daily 24 - Hour Recall Pain Intensity Scores at Week 14 in Adult Subjects with Fibromyalgia (Trials 1 and 3) TONMYA Placebo Change from baseline Value Change from baseline Value Visit / Statistics Trial 1 Baseline 248 255 N 6.1 (1.06) 6.0 (1.08) Mean (SD) (4, 9) (4, 9) (Minimum, Maximum) Week 14 - 1.9 (0.12) 4.2 (0.12) - 1.5 (0.12) 4.6 (0.12) LS mean (SE) 1 ( - 2.1, - 1.7) (3.9, 4.4) ( - 1.7, - 1.3) (4.3, 4.8) 95% CI 1 - 0.4 (0.16) Difference in LS mean (SE) ( - 0.7, - 0.1) 95% CI for difference in LS mean 0.010 p - value for difference TONMYA Placebo Change from baseline Value Change from baseline Value Visit / Statistics Trial 3 Baseline 231 225 N 5.9 (1.05) 5.9 (1.08) Mean (SD) (4, 9) (4, 9) (Minimum, Maximum) Week 14 - 1.8 (0.12) 4.1 (0.12) - 1.2 (0.12) 4.7 (0.12) LS mean (SE) 1 ( - 2.0, - 1.6) (3.8, 4.3) ( - 1.4, - 0.9) (4.5, 5.0) 95% CI 1 - 0.7 (0.16) 2 Difference in LS mean (SE) ( - 1.0, - 0.3) 95% CI for difference in LS mean <0.001 p - value for difference Trial 3 (RESILIENT Trial) Trial 1 (RELIEF Trial)

© 2025 Tonix Pharmaceuticals Holding Corp. 13 TONMYA Approval Based on Studies that Demonstrated Significant Improvement in Pain Intensity Scores in Fibromyalgia Patients Pivotal Studies Included in Label Demonstrate Statistically Significant Mean Change from Baseline in Weekly Average of Daily 24 - hour Recall Pain Intensity Scores at Week 14 (RELIEF Trial) (RESILIENT Trial)

© 2025 Tonix Pharmaceuticals Holding Corp. 14 Greater Percentage of Study Participants Taking TONMYA Experienced a Clinically Meaningful (≥30%) Improvement in their Pain after Three Months, Compared to Placebo P e r c e n t o f S u b j e c t s 0 10 20 30 40 50 60 70 80 90 100 Percentage Reduction in Pain ≥ 0 ≥ 10% ≥ 20% ≥ 30% ≥ 40% ≥ 50% ≥ 60% ≥ 70% ≥ 80% ≥ 90% ≥ 100% Placebo TONMYA 30% Responders (46% TONMYA vs 27% placebo) P e r c e n t o f S u b j e c t s 0 10 20 30 40 50 60 70 80 90 100 Percentage Reduction in Pain ≥ 0 ≥ 10% ≥ 20% ≥ 30% ≥ 40% ≥ 50% ≥ 60% ≥ 70% ≥ 80% ≥ 90% ≥ 100% Placebo TONMYA 30% Responders (47% TONMYA vs 35% placebo) Trial 3 (RESILIENT Trial)* Trial 1 (RELIEF Trial)* *The figures shows the percentage of patients in Trials 1 and 3 who achieved various degrees of improvement in the change from baseline to Week 14 in the weekly averages of daily diary pain scores . The figures are cumulative so that patients whose change from baseline is, for example, 30 % , are also included at every level of improvement below 30 % . Patients who did not complete the trial were assigned 0 % improvement .

© 2025 Tonix Pharmaceuticals Holding Corp. 15 • Fibromyalgia is not a “Diagnosis of Exclusion” (ACR 2016 Criteria) • “ A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses.” 1 • Tender Points are not required to diagnose fibromyalgia • The 2016 ACR criteria specifically eliminated the 1990 requirement 2 for tender points • Changes in mean pain cannot be compared between different studies • Mean pain changes vary between trials even for the same drug, same inclusion criteria and same statistical methods • TONMYA’s registrational studies evaluated a different population of fibromyalgia patients (ACR 2016 criteria) than the prior approved products’ studies (ACR 1990 criteria) • TONMYA also employed more rigorous analytic methods to account for “missing data” (earlier trials used single imputation methods; TONMYA Trials used multiple imputation) • Expert Consensus holds that “Clinically Meaningful” is a ≥ 30% reduction in pain from baseline 3,4 Opportunities to Educate the Community about Fibromyalgia 1 Wolfe F, et al. Semin Arthritis Rheum. 2016. 46(3):319 - 329. doi : 10.1016/j.semarthrit.2016.08.012. 2 Wolfe F, et al. Arthritis Rheum . 1990. 33(2):160 - 72. doi : 10.1002/art.1780330203. 3 Dworkin RH, et al., J Pain . 2008. 9(2):105 - 21. doi : 10.1016/j.jpain.2007.09.005. 4 Arnold LM, et al., Arthritis Rheum. 2012. 64(3):885 - 894. doi:10.1002/art.33360.

© 2025 Tonix Pharmaceuticals Holding Corp. 16 • TONMYA’s studies enrolled patients based on the ACR 2016 criteria, while the prior FDA approved products’ studies used the ACR 1990 criteria • The 1990 ACR criteria required physical exams and the presence of tender points. • The 2016 ACR criteria eliminated the requirement for physical exams and the presence of tender points • The fibromyalgia patient population identified by the 2016 ACR criteria are more representative of how fibromyalgia is diagnosed and treated today • Physical exam and tender point exams are not necessary to diagnose fibromyalgia and are incompatible with, for example, telehealth • New ACR criteria achieved improved sensitivity by focusing on distribution of pain and the severity of other symptoms • Tender - point exams weren’t reliable and did not reflect the full symptom burden Patients Identified by the 2016 ACR criteria More Representative of Current Fibromyalgia Treatment Paradigm 1 Wolfe F, et al. Semin Arthritis Rheum. 2016 46(3):319 - 329. doi : 10.1016/j.semarthrit.2016.08.012. 2 Wolfe F, et al. Arthritis Rheum . 1990. 33(2):160 - 72. doi : 10.1002/art.1780330203. 3 Ablin JN, Wolfe F. J Rheumatol . 2017 Aug;44(8):1271 - 1276. doi : 10.3899/jrheum.170095.

© 2025 Tonix Pharmaceuticals Holding Corp. 17 • Mean pain changes vary between trials even for the same drug, same inclusion criteria and same statistical methods • TONMYA’s registrational studies evaluated a different population of fibromyalgia patients (ACR 2016 criteria) than the prior FDA approved products’ studies (ACR 1990), which required tender points 1 ,2 • TONMYA employed rigorous and conservative analytic methods to account for “missing data” • The prior FDA approved products’ studies used single imputation (i.e. last observation carried forward, LOCF) to account for missing data • LOCF assumes missing data are ignorable which can introduce bias and falsely enhance statistical precision 3 • The primary statistical analyses for the TONMYA registrational studies used multiple imputation, with missing values imputed drawing from baseline values when patients dropped out due to adverse events (AEs) or lack of efficacy 4 • Drugs with tolerability issues and high rates of drop - outs for AEs would be expected to be penalized by the modern missing data treatment requirements employed in TONMYA’s registrational trials Mean Pain Changes Cannot be Compared Between Studies 1 Wolfe F, et al. Semin Arthritis Rheum. 2016 46(3):319 - 329. doi : 10.1016/j.semarthrit.2016.08.012. 2 Wolfe F, et al. Arthritis Rheum . 1990. 33(2):160 - 72. doi : 10.1002/art.1780330203. 3 Woolley SB, et al. Pharmacotherapy . 2009. 29:1408 - 1416 4 Drops - outs due to AEs or LOE are non - ignorable missing data

© 2025 Tonix Pharmaceuticals Holding Corp. 18 • Expert consensus holds that “Clinically Meaningful” in fibromyalgia is defined by a 30% or greater reduction in pain from baseline 1,2 “Clinically Meaningful” Defined by 30% Pain Reduction 1 Dworkin RH, et al., J Pain . 2008. 9(2):105 - 21. doi : 10.1016/j.jpain.2007.09.005. 2 Arnold LM, et al., Arthritis Rheum. 2012. 64(3):885 - 894. doi:10.1002/art.33360. 3 uncorrected p - value p - value 3 Placebo TONMYA p= 0.006 34.9% 46.8% Study 1 (RELIEF) p <0.001 27.1% 45.9% Study 2 (RESILIENT) Percentage of Patients with 30% or greater Reduction in Pain from Baseline to Week 14 Pre - specified Analyses

© 2025 Tonix Pharmaceuticals Holding Corp. 19 • In Clinical Studies: • The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA - treated patients compared to placebo - treated patients) were: oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer • Weight gain, and blood pressure for drug group were similar to placebo group at baseline and to the end of treatment • There were no reports of cognitive dysfunction or sexual dysfunction • No evidence of abuse potential • Pregnancy testing is recommended in females of reproductive potential prior to initiating treatment with TONMYA • Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome For full prescribing information and safety information, please visit www.tonmya.com Generally Well Tolerated with an Established Safety Profile

© 2025 Tonix Pharmaceuticals Holding Corp. 20 Sublingual CBP enters the bloodstream directly through the mucosal membrane TONMYA is a Tertiary Amine Tricyclic that Bypasses First - Pass Liver Metabolism, Leading to Faster Absorption and Reduced norCyclobenzaprine (“ norCBP ”) tongue TONMYA is administered sublingually The sublingual tablet rapidly disintegrates, dissolves, and releases solubilized cyclobenzaprine (“CBP”) into the saliva adjacent to the mucosal membrane The base drives formation of CBP free - base, which enters the bloodstream across the mucosal membrane (transmucosal absorption) Tonix’s proprietary formulation contains a basic ingredient which drives transmucosal absorption and a cyclobenzaprine - mannitol eutectic that results in a stable tablet with a 4 - year shelf - life. CH 3 N CH 3 Transmucosal CBP administered sublingually bypasses “first - pass” liver metabolism, leading to faster absorption and reduced norCBP CH 3 N CH 3 Tertiary amine tail + + + + + + + + + + + Free - base cyclobenzaprine Charged cyclobenzaprine Mannitol Sublingual vasculature

© 2025 Tonix Pharmaceuticals Holding Corp. 21 TONMYA: Patents and Patent Applications • U.S. Composition:* ̶ A 75:25 cyclobenzaprine HCl - mannitol eutectic (dependent claims add a basifying agent). • 5 US Patents (Expire November 2034) • 1 Pending US Application (Would expire November 2034) ̶ A composition of a cyclobenzaprine HCl and a basifying agent suitable for sublingual absorption. • 1 Pending US Application (Would expire June 2033) • U.S. Methods of Use* (Specific Indications): ̶ Fibromyalgia • Pain, Sleep Disturbance, Fatigue ̶ 1 Pending US Application (Would expire December 2041) • Early Onset Response ̶ 1 Pending US Provisional Application (Would expire December 2044) • Depressive Symptoms ̶ 1 Pending US Application (Would expire March 2032) ̶ Sexual Dysfunction • 1 Pending US Application (Would expire October 2041) ̶ PASC • 1 Pending US Application (Would expire June 2043) ̶ PTSD • 1 US Patent (Expires November 2030) ̶ Agitation (Dementia) • 1 US Patent (Expires December 2038) • 1 Pending US Application (Would expire December 2038) ̶ Alcohol Use Disorder • 1 Pending US Application (Would expire November 2041) • Foreign Filings ̶ Corresponding foreign patents have been filed and some have issued: • Composition (25 patents, 3 allowed applications, 16 pending applications) • Methods of Use (9 patents, 54 pending applications) *US Patents: Issued: US Patent Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321. Pending: US Patent Application Nos. 13/918,692; 18/385,468; 13/412,571; 18/265,525; 63/612,352; 18/382,262; 18/037,815; 17/226,058; 18/212,500. Patents based on TONMYA’s eutectic composition and its properties have issued in the U.S., E.U., Japan, China and many other jurisdictions around the world and provide market protection into 2034. The European Patent Office’s Opposition Division maintained Tonix’s European Patent EP 2 968 992 in unamended form after an Opposition was filed against it by a Sandoz subsidiary, Hexal AG. Hexal AG did not appeal that decision.

© 2025 Tonix Pharmaceuticals Holding Corp. 22 Both Patients and HCPs are Challenged by the Fibromyalgia Journey 1 1 Market research commissioned by Tonix, January 2025 PATIENTS HCPs FRUSTRATED isolated passed around do less validation unpredictable side effects embarrassed getting worse still tired when I wake up patient variability waning efficacy trial - and - error side effects comorbidities whack - a - mole mood & pain disrupted sleep lack of options

© 2025 Tonix Pharmaceuticals Holding Corp. 23 Patient and HCP Dissatisfaction has Led to Significant Off - label Use Off - label Opioids are Commonly Prescribed within 18 Months of Fibromyalgia Diagnosis CBP, cyclobenzaprine; NSAID, nonsteroidal anti - inflammatory drug; SNRI, serotonin norepinephrine reuptake inhibitor; TCA, tricyc lic antidepressant. Eversana analysis of claims database, May 2024.

© 2025 Tonix Pharmaceuticals Holding Corp. 24 ~5% of Fibromyalgia - Diagnosing HCPs Write ~70% of Fibromyalgia Prescriptions 1,2 WE WILL GO FROM: Traditional specialty - based decile targeting TO: Hyper - focused 1:1 HCP targeting based on ideal patient types Total Fibromyalgia - Diagnosing HCP Universe 470K ~25K HCPs 1,2 Paid Rx (APLD) in the recent 12 months (Feb’24 to Jan’25); Rx (FACT) in the recent 12 months (Feb’24 to Jan’25); FBM DX 202 0 - 2 025. This 5% also diagnoses 70% of fibromyalgia patients.

© 2025 Tonix Pharmaceuticals Holding Corp. 25 Using our Omnichannel Approach to Empower Reps and Engage Top - prescribing HCPs AMPLIFICATION DIRECT SUPPORT Earned Media Corporate Communications Influencer Marketing Owned Social Channels Reputation Management KOL Engagement Search Engine Optimization Digital Media Paid Social Machine Learning Sales Force 1 (~90 Reps initially) 1 Tonix has engaged Inizio , a leading contract sales organization, to provide the majority of its sales force.

© 2025 Tonix Pharmaceuticals Holding Corp. 26 Robust Patient Access & Support Services On Track to be in Place at Launch Payer Education & Engagement Payer Research and Value Analysis Pre - Approval Information Exchange Meetings Burden of Disease & Payer Value Proposition Traditional Pharmacy Savings Program Copay Support for Eligible Patients Digital & Text Enrollment Prior Authorization Support ACCESS PATHWAYS 1 1 Programs are for patients after their HCP has determined TONMYA is appropriate for them. Digital Pharmacy Experience Bridge Program Streamlined Enrollment & Enhanced Prior Authorization Support Free Home Delivery, Enhancing Convenience and Access

© 2025 Tonix Pharmaceuticals Holding Corp. 27 TONMYA will Join Tonix Medicine’s Two Existing Proprietary CNS Drugs: Both are Non - Oral Formulations of Sumatriptan • TOSYMRA ® and ZEMBRACE ® are each indicated for the tr eatment of acute migraine with or without aura in adults • Sumatriptan remains the acute migraine ‘gold standard’ treatment for many patients and continues to represent the largest segment of the market in terms of unit sales 3 • Each may provide migraine pain relief in as few as 10 minutes for some patients 1,2,4,5 • Patents to 2036 (ZEMBRACE) and 2031 (TOSYMRA) 1 ZEMBRACE SymTouch [package insert] . For more information, talk to your provider and read the Patient Information and Instructions for Use . – Important Safety Information is provided in the appendix 2 TOSYMRA [package insert ]. For more information, talk to your provider and read the Patient Information and Instructions for use – Important Safety Information is provided in the appendix 3 Tonix Medicines, Inc.; Data On File, 2023 ZEMBRACE® SymTouch® (sumatriptan injection) 3 mg 1 TOSYMRA® (sumatriptan nasal spray) 10 mg 2 Tonix Medicines Commercial Subsidiary: Complete Commercialized Capabilities & Infrastructure • Trade, Managed Care & Government contracting • Team of professionals including Sales, Marketing, and Medical Affairs personnel • Manage supply chain and contract manufacturers • Distribution 4 Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatri pta n Research Group. Arch Neurol. 1992;49(12):1271 - 1276. 5 Wendt J, et al. A randomized, double - blind, placebo - controlled trial of the efficacy and tolerability of a 4 - mg dose of subcutan eous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517 - 526. ZEMBRACE SymTouch and TOSYMRA are registered trademarks of Tonix Medicines, Inc. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly owned subsidiary of Neurelis , Inc.

© 2025 Tonix Pharmaceuticals Holding Corp. 29 Key Clinical and Preclinical Programs PHASE 3 PHASE 2 PHASE 1 PRE C LINICAL INDICATION MOLECULE* Treatment of Acute Stress Disorder TNX - 102 SL Cyclobenzaprine HCl Sublingual Tablets CNS Treatment of Major Depressive Disorder TNX - 102 SL Cyclobenzaprine HCl Sublingual Tablets Prevention of Organ Transplant Rejection/ Treatment of Autoimmune Conditions TNX - 1500 Anti - CD40L mAb Immunology and i mmuno - oncology Preclinical Treatment of Gastric and Colorectal Cancer TNX - 1700 TFF2 - HSA Fusion Protein Seasonal Prevention of Lyme Disease TNX - 4800 Monoclonal Antibody Infectious d isease Preclinical Prevention of Mpox or Smallpox TNX - 801 Live Virus Horsepox Vaccine Preclinical Protection of the Warfighter F rom Viral Pathogens TNX - 4200 Broad Spectrum Antiviral Treatment of Prader - Willi Syndrome TNX - 2900 Intranasal Potentiated Oxytocin (OT) W ith Magnesium Rare d isease *All of Tonix Pharmaceuticals ' product candidates are investigational new drugs or biologics; their safety and efficacy have not been established for the listed indication. **Investigator - initiated study . ***Pending IND filing planned for Q4 2025. Topline Expected 2nd Half 2026 Phase 2 Study Enrolling** Topline Reported 1st Quarter 2025 Phase 1 Study Completed Phase 2/3 Study Planned Phase 2 Study Planned 2026 Phase 2 Study Ready***

© 2025 Tonix Pharmaceuticals Holding Corp. Tonix’s scientific expertise validated by numerous mutually beneficial government and academic collaborations • Reduces internal spend • Increases number of trials • Potentially speeds time to market • Grants, contracts, cost - sharing or “in - kind” arrangements TNX - 1500: ALLOGRAFT REJECTION TNX - 2900: PRADER - WILLI SYNDROME TNX - 102 SL: ACUTE STRESS DISORDER TNX - 4200: BROAD - SPECTRUM ANTIVIRAL 30 TNX - 4800: SEASONAL LYME PREVENTION

© 2025 Tonix Pharmaceuticals Holding Corp. 31 Tonix Research and Development Center (RDC) • Supports expanding infectious disease pipeline by accelerating internal discovery and development of vaccines and antiviral drugs • Located in Frederick, MD (close to Fort Detrick/ USAMRIID) • 48,000 square foot facility • Main building is BSL - 2 with certain areas designated BSL - 3 • At full capacity, the RDC can employ up to 100 scientists and technical support staff

© 2025 Tonix Pharmaceuticals Holding Corp. Phase 2 Trial in Partnership with: Large unmet need: • According to National Center for PTSD, about 60% of men and 50% of women in the US are exposed least one traumatic experience in their lives 1 • In the US alone, one - third of emergency department visits (40 - 50 million patients per year) are for evaluation after trauma exposures 2 OASIS trial will build upon infrastructure developed through the UNC - led, $40M AURORA initiative, a major national research initiative to improve the understanding, prevention, and recovery of individuals who have experienced a traumatic event Status: Phase 2 Investigator Initiated Study (“OASIS”) currently enrolling patients TNX - 102 SL For Acute Stress Reaction (ASR) / Acute Stress Disorder (ASD) ASR/ASD are acute stress conditions resulting from trauma which can affect both civilian and military populations. Current standard of care: • No medications are currently available at or near the point of care to treat patients suffering from acute traumatic events and support long - term health 32 1 National Center for PTSD. How Common is PTSD in Adults? https://www.ptsd.va.gov/understand/common/common_adults.asp 2 Wisco et al. J Clin Psychiatry . 2014.75(12):1338 - 46

© 2025 Tonix Pharmaceuticals Holding Corp. Potential Pivotal Phase 2 Trial planned: double - blind, placebo - controlled study in Major Depressive Disorder (MDD), targeting moderate - to - severe depression, including in older adults, with the 5.6 mg dose. Plan to initiate enrollment in 2026 Large unmet need: • Depression is a problem/remains an unmet need despite multiple approved drugs 1 • ~21 million U.S. adults annually experience at least one major depressive episode 2 Evidence: TNX - 102 SL showed activity on the Beck Depression Inventory - II (BDI) in the Phase 3 RESILIENT study in fibromyalgia patients with an uncorrected p - value < 0.05. The BDI - II was a pre - specified exploratory endpoint. The biological relationship between depressive symptoms in fibromyalgia and those in major depressive disorder is not clear Status: Successful pre - IND meeting; planning to submit IND in 4Q 2025. Plan to pursue a supplemental new drug application ( sNDA ) for MDD for TNX - 102 SL, which is already FDA - approved for treating fibromyalgia TNX - 102 SL For Major Depressive Disorder (MDD) TNX - 102 SL is believed first - in - class for targeting the disturbed sleep associated with depression Current standard of care: • SSRIs, SNRIs, dextromethorphan/bupropion • Secondary amine tricyclic antidepressants • Tertiary amine tricyclic antidepressants • Swallowed pill formulations, that are largely metabolized by first - pass to longer - lived secondary amine tricyclics, are active in treating depression at doses which can adversely impact weight, blood pressure/heart rate, cognition, and sexual function 33 1 Rush, et al Am J Psychiatry. 2006 Nov;163(11):1905 - 17 ; Garcia - Marin et al. Annals of General Psychiatry (2023) 22:49 2 www.nimh.nih.gov/health/statistics/major - depression

34 © 2025 Tonix Pharmaceuticals Holding Corp. CNS PORTFOLIO TNX - 102 SL: P hase 3 RESILIENT Study Design General s tudy c haracteristics: • Randomized, double - blind, multicenter, placebo - controlle d study in fibromyalgia • 33 U.S. sites enrolled 457 participants with fibromyalgia as defined by 2016 Revisions to the 2010/2011 FM Diagnostic Criteria 1 Primary Endpoint: • Change from baseline to Week 14 (TNX - 102 SL vs. placebo) in weekly averages of daily diary average pain severity score • Primary Endpoint, p - value = 0.00005 Placebo once - daily at bedtime TNX - 102 SL once - daily at bedtime 5.6 mg (2 x 2.8 mg tablets) * * Two - week run - in at 2.8 mg dose at bedtime followed by 12 weeks at 5.6 mg dose ClinicalTrials.gov Identifier: NCT05273749 Study Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TNX - 102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT) Trial ID: TNY - CY - F307 (‘RESILIENT’) 14 weeks 1 Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016; 46(3):319 - 329.

35 © 2025 Tonix Pharmaceuticals Holding Corp. CNS PORTFOLIO RESILIENT : FIQR Individual Items 1 Affective Symptoms, Sensory Sensitivity, Cognition, and Energy Pre - specified exploratory endpoints Selected Fibromyalgia Impact Questionnaire - Revised Symptoms Domain Item Scores Pre - specified exploratory endpoints Effect Size P - value^ 95% Confidence Interval # Week 14 LS Mean (SE) Difference from Placebo # FIQ - R Item Please rate your level of... (past 7 days) 0.35 <0.001 - 1.2, - 0.6 - 0.8 (0.21) Depression 0.30 0.001 - 1.2, - 0.3 - 0.8 (0.24) Anxiety 0.22 0.020 - 1.0, - 0.1 - 0.6 (0.24) Sensitivity to…* 0.31 0.001 - 1.2, - 0.3 - 0.8 (0.23) Memory problems 0.31 <0.001 - 1.2, - 0.3 - 0.8 (0.23) Energy *…loud noises, bright lights, odors, and cold 1 FIQR=Fibromyalgia Impact Questionnaire - Revised # Mixed model repeated measures analysis (no imputation); fixed categorical effects of treatment, site, study week, and treatme nt x study week interaction; fixed covariates of baseline value and baseline value x study week interaction ^Uncorrected for multiple comparisons

36 © 2025 Tonix Pharmaceuticals Holding Corp. CNS PORTFOLIO RESILIENT : Beck Depression Inventory - II Pre - specified Exploratory Endpoint Effect Size P - value 95% CI for Difference Difference in LS Means (SE) TNX LS MCFB (SE) TNX Mean (SD) Placebo LS MCFB (SE) Placebo Mean (SD) 9.6 (6.32) 10.0 (6.72) Baseline 0.27 0.005 # - 2.3, - 0.4 - 1.4 (0.49) - 3.4 (0.35) - 2.0 (0.35) Week 14 -4.5 -4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 0 2 6 10 14 Mean (SE) Change from Baseline of BDI - II Week of Study Beck Depression Inventory - II Change from Baseline to Week 14 Placebo TNX-102 SL **p<0.01; ***p<0.001 ** *** ** • Greater reduction in total BDI - II score in TNX - 102 SL group over placebo at Week 14 with p=0.005 # , effect size of 0.27 • Also separated, with p<0.01 # , at Week 2 when on TNX - 102 SL 2.8 mg first two weeks • And separated, with p<0.001 # , at Week 6 # Uncorrected for multiple comparisons SE=standard error; SD=standard deviation

37 © 2025 Tonix Pharmaceuticals Holding Corp. CNS PORTFOLIO RESILIENT : Summary of Baseline Depression BDI - II and FIQR Item • While the rate of current MDE diagnosis was ~2% of the ITT, ~25% ITT had experienced a lifetime MDE, and ~47% reported depression during prior 6 months on FM Dx* • Also, about 25% of the ITT enrolled on concomitant antidepressant or buspirone • By end of treatment (Week 14), there was a greater reduction in depression severity by total BDI - II score in TNX - 102 SL group compared with placebo (p=0.005) ‒ And greater reduction in FIQR items for depression (p<0.001), anxiety (p=0.001), and sensory sensitivity (p=0.020) in the TNX - 102 SL group compared with placebo ‒ The FIQR memory item, a measure of cognitive impairment in FM, was more improved in the TNX - 102 SL group than placebo (p=0.001) ‒ The FIQR energy item, another indicator of less fatigue in FM, was also more improved in the TNX - 102 SL group than placebo (p<0.001) • Cohen’s d effect sizes were between 0.27 and 0.35 for all Week 14 outcomes above except sensory sensitivity *Wolfe F, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016; 46(3):319 - 329 . Abbreviations: BDI - II, Beck Depression Inventory - II; Dx, diagnosis; FIQR, Fibromyalgia Impact Questionnaire - Revised; FM, fibromyalgia; ITT, Intention - to - Treat

38 © 2025 Tonix Pharmaceuticals Holding Corp. CNS PORTFOLIO RESILIENT Safety Summary Among participants randomized to TNX - 102 SL and to placebo, 81.0% and 79.6%, respectively, completed the study TNX - 102 SL was generally well tolerated with an adverse event (AE) profile comparable to prior fibromyalgia studies • No new safety signals were observed • AE - related study discontinuations occurred in 6.1% and 3.6% of patients in the TNX - 102 SL and placebo groups, respectively • Events rated as mild or moderate made up 97.2% of AEs on placebo and 99.1% on TNX - 102 SL • As observed in prior studies with TNX - 102 SL, oral administration site AEs were higher in TNX - 102 SL than placebo, 42.9% and 10.2%, respectively ‒ Most common oral AEs were oral hypoaesthesia , product taste abnormal, oral paraesthesia , and tongue discomfort (see table on next slide) ‒ Nearly all of these common oral AEs were temporally related to dosing and typically lasted <60 minutes • Serious Adverse Events (SAEs) ‒ Three placebo participants experienced an SAE: ▪ 1. Pneumonia, 2. Muscular weakness, and 3. Hypertension/Angina/Coronary Artery Disease ‒ Two TNX - 102 SL participants experienced an SAE ▪ 1. Renal carcinoma deemed not related to study drug ▪ 2. Acute pancreatitis with onset 14 days after completion of treatment phase, deemed ‘possibly related’* to study drug ⁃ Outcome: ‘Recovered/Resolved’

39 © 2025 Tonix Pharmaceuticals Holding Corp. CNS PORTFOLIO RESILIENT Safety Total* N=457 Placebo N=226 TNX - 102 SL N=231 System Organ Class Preferred Term Systemic Adverse Events 17 (3.7%) 7 (3.1%) 10 (4.3%) COVID - 19 10 (2.2%) 3 (1.3%) 7 (3.0%) Somnolence 11 (2.4%) 4 (1.8%) 7 (3.0%) Headache Oral Cavity Adverse Events 56 (12.3%) 1 (0.4%) 55 (23.8%) Hypoaesthesia oral 29 (6.3%) 2 (0.9%) 27 (11.7%) Product taste abnormal 18 (3.9%) 2 (0.9%) 16 (6.9%) Paraesthesia oral 16 (3.5%) 0 (0.0%) 16 (6.9%) Tongue discomfort Treatment - Emergent Adverse Events (TEAEs) at Rate of ≥ 3% in Either Treatment Group

© 2025 Tonix Pharmaceuticals Holding Corp. TNX - 1500 1 Next (Third) Generation ߙ - CD40 Ligand (CD40L) Antibody The CD40 - CD40L pathway is a pivotal immune system modulator and a well - established and promising treatment target First Generation: Development halted due to thromboembolic (TE) complications — blood clots — traced to Fc gamma receptor (Fc ઻ R) Prevention of Allograft and Bone Marrow Transplant Rejection Status: Phase 1 study – completed Collaborations ongoing with Mass General Hospital on heart and kidney transplantation in non - human primates • Collaboration with Boston Children’s on bone marrow transplantation in non - human primates Next Steps: Initiate Phase 2 study in Kidney Transplant Recipients SELECTIVELY MODIFIED anti - CD40L AB Ruplizumab full Fab Contains the full ruplizumab Fab and the engineered Fc region that modulates Fc γ R - binding, while preserving FcRn function. Mutated Fc γ R - binding region FcRn - binding region Fc γ R - modulated Fc region Second Generation: Eliminated the Fc ઻ R TE complication but potency and half life was reduced, limiting utility Third Generation (TNX - 1500): Re - engineered to better modulate the binding of Fc ઻ R. 1 TNX - 1500 has not been approved for any indication. Patents filed. Differentiators: Expected to deliver efficacy without compromising safety Autoimmune Diseases Status: Potential future indications include: Sjögren’s Syndrome, Systemic Lupus Erythematosus • These indications require large studies, but represent large target markets 40

© 2025 Tonix Pharmaceuticals Holding Corp. 41 TNX - 1500 Phase 1 Topline Results and Conclusions Phase 1: single ascending dose study in healthy participants to evaluate safety and pharmacokinetics/pharmacodynamics (PK/PD) • At total of 26 participants were enrolled in three cohorts ( 3 mg/kg, 10 mg/kg, and 30 mg/kg i.v. ) Topline results • Pharmacodynamics (PD): TNX - 1500 blocked the primary and secondary antibody responses to a test antigen (KLH) at the 10 and 30 mg/kg i.v. doses • Pharmacokinetics (PK) : mean half - life (t 1/2 ) for the 10 mg/kg and 30 mg/kg doses of 34 - 38 days • TNX - 1500 was generally well - tolerated with a favorable safety profile • Tolerability: TNX - 1500 was generally well - tolerated with a favorable safety and tolerability profile. The only TEAE occurring in ≥ 3 participants among all TNX - 1500 groups was Aphthous ulcer, occurring in one participant each in the 3 mg/kg, 10 mg/kg, and 30 mg/kg groups; all were rated as mild, possibly related, and resolved in 2 - 10 days. Conclusions • Results support proceeding to develop Phase 2 trial for the prevention of kidney transplant rejection • Fc modifications we engineered to TNX - 1500 for safety did not attenuate the potency of TNX - 1500 relative to humanized 5c8 (hu5c8, ruplizumab, BG9588) 1 - 3 • We believe the results of this study and our prior animal studies 4,5 indicate that TNX - 1500 is potentially best - in - class among anti - CD40L mAbs in development 1 Lederman S, et al, J Exp Med . 1992 Apr 1;175(4):1091 - 101. doi : 10.1084/jem.175.4.1091. PMID: 1348081; PMCID: PMC2119166. 2 Boumpas DT, et. al. Arthritis Rheum . 2003;48(3):719 - 27. doi : 10.1002/art.10856. PMID: 12632425. 3 Pierson RN 3rd, et al. Transplantation . 1999;68(11):1800 - 5. doi : 10.1097/00007890 - 199912150 - 00026. PMID: 10609959. 4 Lassiter G, et al. Am J Transplant . 2023;23(8):1171 - 1181. doi : 10.1016/j.ajt.2023.03.022. 5 Miura S, et al. Am J Transplant . 2023;23(8):1182 - 1193. doi : 10.1016/j.ajt.2023.03.025.

© 2025 Tonix Pharmaceuticals Holding Corp. TNX - 1700 1 Gastric and Colorectal Cancers Recombinant Trefoil Factor 2 (hTFF2) Fusion Protein Mechanism of Action : suppresses myeloid - derived suppressor cells and activates anti - cancer CD8+ T cells Potential synergies with anti - PD - 1 or antil - PD - L1 monoclonal antibodies (mAbs) Licensed from Columbia University: developing in partnership under sponsored research agreement. Patents filed. Preclinical Evidence for Inhibiting Growth of Cancer Cells • Data showed that mTFF2 - CTP augmented the efficacy of mAb anti - PD - 1 therapy. Anti - PD - 1 in combination with mTFF2 - CTP showed greater anti - tumor activity in PD - L1 - overexpressing mice mTNX - 1700 (mTFF2) has effects on cancer by altering the tumor micro - environment Differentiator: No product yet identified consistently augments PD1 effects on cold tumors 1 TNX - 1700 is in the pre - IND stage of development and has not been approved for any indication. 2 Dubeykovskaya Z, et al. J Biol Chem. 2009;284(6):3650 - 3662. 3 Balkwill F. Semin Cancer Biol. 2004;14(3):171 - 179. 4 Teixidó J, et al. Int J Biochem Cell Biol. 2018;95:121 - 131. Status: • Preclinical, progressing to IND Market Entry: • Immuno - oncology, combination therapy with PD1 blockers for gastric and colorectal cancer 42

© 2025 Tonix Pharmaceuticals Holding Corp. 43 TNX - 1700 – Recent Publication in Cancer Cell 1 43 • Combination treatment of mTNX - 1700 (mTFF2 - MSA fusion protein) with anti - PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti - PD1 treatment alone • mTNX - 1700 treatment was associated with activation of cancer - killing CD8+ T Cells and limiting neutrophil - mediated immune evasion 1 Qian J, et al. Cancer Cell. 2025. 43(8):1512 - 1529.e11. doi : 10.1016/j.ccell.2025.06.006 .

© 2025 Tonix Pharmaceuticals Holding Corp. TNX - 801 1 Recombinant Pox Vaccine (RPV) Platform Using Live Virus Technology Economical to manufacture at scale: l ow dose because replication amplifies dose in vivo single administration Standard refrigeration for shipping and storage: believed to be stable without freezing (thermostable) in ultimate lyophilized formulation Attenuated, minimally replicative, live virus • Based on synthetic horsepox - vector, believed related to first smallpox vaccine used by Dr. Edward Jenner in 1796 3 • Single - dose subcutaneous 3,4 • Expected durable T - cell immunity similar to 19th Century vaccinia Cloned version of horsepox 2 purified from cell culture Differentiators: Live virus vaccines are the most established vaccine technology. Prevents forward transmission and effective in eliciting durable or long - term immunity 1 TNX - 801 is in the pre - IND stage of development and has not been approved for any indication. 2 Noyce et al., 2018. PLoS One . 13(1):e0188453 . 3 Noyce RS, et al. Viruses . 2023 5(2):356. Doi: 10.3390/v15020356. PMID: 36851570; PMCID: PMC9965234 4 Bavari, S. July 10, 2025. Presentation: World Congress on Vaccines (Vienna). “TNX - 801, a single - dose live vaccine platform for Mpox and other emerging viral diseases: Safety, Immunogenicity, and Efficacy” Design supports potential real - world effectiveness • One - dose vaccine, allows for ring vaccination strategy and eliminates dropouts between doses • Working to develop microneedle one - dose delivery to drive local accessibility 44

© 2025 Tonix Pharmaceuticals Holding Corp. TNX - 4800 1 Monoclonal antibody prophylaxis for Lyme Disease Advantages of TNX - 4800 relative to vaccines in development: provides protection after first dose, does not require a host immune response Phase 1 data showed prolonged levels of TNX - 4800 consistent with protection throughout the tick season: from Spring to Fall in the U.S. Monoclonal Antibody Attacks Borrelia • When the tick bites a human host who has been given TNX - 4800, the anti - OspA antibodies will enter the tick midgut, binding to OspA proteins on the outer lipid membrane of B. burgdorferi 3,4 • Once OspA has been targeted, the bacteria cannot migrate from the tick’s midgut to the tick’s salivary glands or then to the human host 2 • A mutation in the Fc region of the TNX - 4800 antibody extends its half - life, allowing a single administration to provide protection throughout the months of greatest infection risk Long Acting anti - OspA monoclonal antibody 2 - 4 to block Borrelia Burgdorferi transfer Differentiators: Immediate protection 1 TNX - 4800 has not been approved for any indication. 2 Schiller ZA, al. J Clin Invest . 2021;131(11):e144843. 3 de Silva AM, et al. J Exp Med . 1996;183(1):271 - 275. 4 Radolf JD, et al. Nat Rev Microbiol . 2012;10(2):87 - 99. Long - Acting Antibody: Seasonal Duration 45 B. burgdorferi Outer lipid membrane OspA / OspC Outer membrane protein Lipoprotein BamA Plan to initiate an adaptive Phase 2/3 trial in 2027

© 2025 Tonix Pharmaceuticals Holding Corp. TNX - 4200 1 Broad - spectrum Host - directed Therapeutics: CD45 Inhibitor as Antiviral Department of Defense Contract : awarded Tonix a $34M contract over five years to advance development of TNX - 4200 for medical countermeasures Broad antiviral application : objective of this program is to find an orally available small molecule inhibitor of CD45 activity and show protection against multiple viral infections Department of Defense Contract • Represents a move away from “one drug, one bug” approach. Broad antiviral application has potential to protect against multiple viruses (“one drug, multiple bugs”). • Program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an IND submission and to fund a first - in - human Phase 1 clinical study Small molecule therapeutics that reduce endogenous levels of CD45, a protein tyrosine phosphatase Differentiators: Reduction in CD45 has potential to protect against many viruses. 1 TNX - 4200 is in the pre - IND stage of development and has not been approved for any indication. 2 Panchal RG, et al., Cell Host Microbe. 2009 6(2):162 - 73. doi: 10.1016/j.chom.2009.07.003. PMID: 19683682. 3 Panchal RG, et al. J Biol Chem. 2009 284(19):12874 - 85. doi: 10.1074/jbc.M809633200 Enhances v iral immunity by inhibiting CD45 phosphatase • CD45 is a transmembrane protein tyrosine phosphatase (PTPase) expressed on most hematopoietic cells, including T lymphocytes • CD45 regulates receptor signaling pathways, particularly T cell activation • D ephosphorylates the negative regulatory tyrosine kinases (e.g., lck and src) • Decreased levels of CD45 enhance antiviral 2 and antibacterial immunity in animals 3 46

© 2025 Tonix Pharmaceuticals Holding Corp. TNX - 2900 1 Intranasal Potentiated Oxytocin (OT) with Magnesium Prader - Willi Syndrome: is the most common genetic cause of life - threatening childhood obesity • Rare disease occurring in 1 in 10,000 to 1 in 30,000 births • Symptoms include lack of suckling as infants, poor muscle strength, and constant hunger (hyperphagia) in adolescents and young adults In animal models: Oxytocin has improved suckling and suppressed hunger Market Entry: • Treatment of children and adolescents with Prader - Willi Syndrome In development for Prader - Willi Syndrome, a rare disease. Differentiators: Tonix’s patented potentiated OT formulation is believed to increase activity of OT at OT receptors (OXTR) 1 TNX - 2900 has not been approved for any indication Status & Next Steps • Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA • Received IND clearance for Phase 2 trial from FDA • Plan to Initiate Phase 2 Trial in 2026 47 Oxytocin receptor Oxytocin Oxytocin Requires Magnesium for Receptor Binding

© 2025 Tonix Pharmaceuticals Holding Corp. 48 Milestones: Recently Completed and Targeted Q1 2025 TNX - 1500 - Topline results from Ph 1 PK/PD study Q2 2025 TNX - 102 SL - Initiated Enrollment in Ph 2 Trial in ASD / ASR Aug 15, 2025 TONMYA - FDA Approval Q4 2025 TONMYA - Expected Commercial Launch Q4 2025 TNX - 102 SL - Submit IND for MDD 2026 TNX - 102 SL - Initiate Ph 2 Trial for MDD 2026 TNX - 2900 - Initiate Ph 2 Trial for PWS

© 2025 Tonix Pharmaceuticals Holding Corp. 50 TONMYA (cyclobenzaprine hydrochloride sublingual tablets) INDICATION: TONMYA is indicated for the treatment of fibromyalgia in adults. Important Safety Information (1 of 2) IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TONMYA is contraindicated: In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may man ife st as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected. With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs. During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturb anc es, or congestive heart failure. In patients with hyperthyroidism. WARNINGS AND PRECAUTIONS Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trime st er of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnanc y t est prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy. Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (S NRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life - threatening condition. Serotonin syndr ome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be disco nti nued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, car efu l observation is advised, particularly during treatment initiation or dosage increases. Tricyclic antidepressant - like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongat io n of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontin uat ion of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored durin g T CA use to identify recurrence of seizures or an increase in the frequency of seizures. Atropine - like effects: Use with caution in patients with a history of urinary retention, angle - closure glaucoma, increased intra ocular pressure, and in patients taking anticholinergic drugs. CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Con com itant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are rea son ably certain that TONMYA therapy will not adversely affect their ability to engage in such activities. Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA comp ar ed to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory ch ang es (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.

© 2025 Tonix Pharmaceuticals Holding Corp. 51 TONMYA (cyclobenzaprine hydrochloride sublingual tablets) INDICATION: TONMYA is indicated for the treatment of fibromyalgia in adults. Important Safety Information (2 of 2) IMPORTANT SAFETY INFORMATION (CONT’D) ADVERSE REACTIONS The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA - treated patients compared to placebo - treate d patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer. DRUG INTERACTIONS MAO inhibitors: Life - threatening interactions may occur. Other serotonergic drugs: Serotonin syndrome has been reported. CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced. Tramadol: Seizure risk may be enhanced. Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked. USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of availa ble observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA - associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pr egnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Ton ix Medicines, Inc., adverse - event reporting line at 1 - 888 - 869 - 7633 (1 - 888 - TNXPMED). Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these da ta cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along wit h the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition. Pediatric use: The safety and effectiveness of TONMYA have not been established. Geriatric patients: Of the total number of TONMYA - treated patients in the clinical trials in adult patients with fibromyalgia, n one were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclo ben zaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA - associated adverse reactions. Please see additional safety information in the full Prescribing Information. To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1 - 888 - 869 - 7633, or the FDA at 1 - 800 - FDA - 1088 or www.fda. gov/medwatch.

© 2025 Tonix Pharmaceuticals Holding Corp. 52 ZEMBRACE® Important Safety Information (1 of 2) ZEMBRACE SymTouch (ZEMBRACE) can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:  D iscomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back; severe tightness, p ain , pressure, or heaviness in your chest, throat, neck, or jaw; pain or discomfort in your arms, back, neck, jaw or stomach ; shortness of breath with or without chest discomfort ; breaking out in a cold sweat ; nausea or vomiting ; feeling lightheaded ZEMBRACE is not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diab ete s, family history of heart disease) unless a heart exam shows no problem. Do not use ZEMBRACE if you have:  H istory of heart problems ; narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease) ; uncontrolled high blood pressure ; hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.  H ad a stroke, transient ischemic attacks (TIAs), or problems with blood circulation ; severe liver problems ; taken any of the following medicines in the last 24 hours: almotriptan , eletriptan , frovatriptan , naratriptan, rizatriptan, ergotamines , dihydroergotamine ; are taking certain antidepressants, known as monoamine oxidase (MAO) - A inhibitors or it has been 2 weeks or less since you stopp ed taking a MAO - A inhibitor. Ask your provider for a list of these medicines if you are not sure.  A n allergy to sumatriptan or any of the components of ZEMBRACE. Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. ZEMBRACE can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you nee d t o be alert.

© 2025 Tonix Pharmaceuticals Holding Corp. 53 ZEMBRACE® Important Safety Information (2 of 2) ZEMBRACE may cause serious side effects including: • Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, na usea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your fe et or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet; increased blood pressure including a sudden severe increase even i f y ou have no history of high blood pressure; medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider. • Serotonin syndrome, a rare but serious problem that can happen in people using ZEMBRACE, especially when used with anti - depressa nt medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbea t; changes in blood pressure; high body temperature; tight muscles; or trouble walking. • Hives (itchy bumps); swelling of your tongue, mouth, or throat • Seizures even in people who have never had seizures before The most common side effects of ZEMRACE include: pain and redness at injection site; tingling or numbness in your fingers or toe s; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired. Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effe cts of ZEMBRACE. For more information, ask your provider. This is the most important information to know about ZEMBRACE but is not comprehensive. For more information, talk to your pr ovi der and read the Patient Information and Instructions for Use . For full Prescribing Information, visit: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e5b104f - 2b9e - 416e - 92fb - ef1bdaea867d You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 - 800 - FDA - 1088. ZEMBRACE is a prescription medicine used to treat acute migraine headaches with or without aura in adults who have been diagn ose d with migraine. ZEMBRACE is not used to prevent migraines. It is not known if it is safe and effective in children under 18 years of age.

© 2025 Tonix Pharmaceuticals Holding Corp. 54 TOSYMRA® Important Safety Information (1 of 2) TOSYMRA® can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop TOSYM RA and get emergency medical help if you have any signs of heart attack: • D iscomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back ; severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw ; pain or discomfort in your arms, back, neck, jaw, or stomach ; shortness of breath with or without chest discomfort; breaking out in a cold sweat ; nausea or vomiting ; feeling lightheaded TOSYMRA is not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam is done and shows no problem. Do not use TOSYMRA if you have: • H istory of heart problems ; narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease) ; uncontrolled high blood pressure ; severe liver problems ; hemiplegic or basilar migraines. If you are not sure if you have these, ask your healthcare provider. • H ad a stroke, transient ischemic attacks (TIAs), or problems with blood circulation ; taken any of the following medicines in the last 24 hours: almotriptan , eletriptan , frovatriptan , naratriptan, rizatriptan, ergotamines , or dihydroergotamine. Ask your provider if you are not sure if your medicine is listed above • are taking certain antidepressants, known as monoamine oxidase (MAO) - A inhibitors or it has been 2 weeks or less since you stopped taking a MAO - A inhibitor . A sk your provider for a list of these medicines if you are not sure • A n allergy to sumatriptan or any ingredient in TOSYMRA Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. TOSYMRA can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.

© 2025 Tonix Pharmaceuticals Holding Corp. 55 TOSYMRA may cause serious side effects including: • Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cramping and pain in your legs or hips, feeling of heaviness or tightness in your leg muscles, burning or aching pain in your feet or toes while resting, numbness, tingling, or weakness in your legs, cold feeling or color changes in one or both legs or feet; increased blood pressure including a sudden severe increase even if you have no history of high blood pressure; medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider . • Serotonin syndrome, a rare but serious problem that can happen in people using TOSYMRA, especially when used with anti - depressant medicines called SSRIs or SNRIs. Call your provider right away if you have : mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking. • Seizures even in people who have never had seizures before The most common side effects of TOSYMRA include : tingling, dizziness, feeling warm or hot, burning feeling, feeling of heaviness, feeling of pressure, flushing, feeling of ti ght ness, numbness, application site (nasal) reactions, abnormal taste, and throat irritation. Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of TOSYMRA. For more information, ask your provider. This is the most important information to know about TOSYMRA but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for use . For full Prescribing Information, visit: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=015a5cf9 - f246 - 48bc - b91e - cd730a53d8aa . You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch , or call 1 - 800 - FDA - 1088. TOSYMRA is a prescription medicine used to treat acute migraine headaches with or without aura in adults. TOSYMRA is not used to treat other types of headaches such as hemiplegic or basilar migraines or cluster headaches. TOSYMRA is not used to prevent migraines. It is not known if TOSYMRA is safe and effective in children under 18 years of age. TOSYMRA® Important Safety Information (2 of 2)